Page 2 of 6
Douglas Krafte, PhD
Douglas Krafte is Senior Vice President of Ion Channels/Transporters at OmniAb and serves as the Icagen Ion Channel Technology Site Head. Dr. Krafte has over 30 years of experience in the pharmaceutical and biotech industry managing research sites and R&D programs. Previously, he was Chief Scientific Officer at Icagen, Inc. and an executive officer there …
10.18.2022
Small-molecule eRF3a degraders rescue CFTR nonsense mutations by promoting premature termination codon readthrough
Rhianna E Lee, Catherine A Lewis, Lihua He, Emily C Bulik-Sullivan, Samuel C Gallant, Teresa M Mascenik, Hong Dang, Deborah M Cholon, Martina Gentzsch, Lisa C Morton, John T Minges, Jonathan W Theile, Neil A Castle, Michael R Knowles, Adam J Kimple, Scott H Randell
09.15.2022
A-type FHFs mediate resurgent currents through TTX-resistant voltage-gated sodium channels
Yucheng Xiao, Jonathan W Theile, Agnes Zybura, Yanling Pan, Zhixin Lin, Theodore R Cummins
04.20.2022
LIGAND AND GSK EXPAND GLOBAL COLLABORATION AND LICENSE AGREEMENT
Ligand to receive an upfront payment of $10 million Further leverages the Icagen ion-channel discovery technology to target neurological diseases EMERYVILLE, Calif.–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today the expansion of an existing collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline (GSK). The expansion will leverage Icagen’s ion-channel-based discovery technology and unique expertise …
12.21.2021
Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series
Andrew M. Griffin, Kristopher M. Kahlig, Robert John Hatch, Zoë A. Hughes, Mark L. Chapman, Brett Antonio, Brian E. Marron, Marion Wittmann, and Gabriel Martinez-Botella
03.01.2021
Page 2 of 6